Federal psilocybin rescheduling — realistic timeline and what's actually happening

The procedural pathway: (1) NDA (New Drug Application) approval from FDA for a specific indication — for psilocybin this would likely be treatment-resistant depression or MDD. (2) After NDA approval, DEA is mandated to reschedule. This is automatic — FDA approval creates the legal mechanism for rescheduling. (3) The DEA then initiates rulemaking, which takes 12-18 months under normal regulatory timelines. So the sequence is: FDA approval first, DEA reschedule second.

Realistic timeline: COMPASS Pathways completed Phase 3 trials. Positive Phase 3 data is necessary but not sufficient for NDA approval — the FDA also evaluates manufacturing, safety data across the full trial history, and REMS (Risk Evaluation and Mitigation Strategy) requirements for controlled substances. Given current regulatory pace, the optimistic estimate for FDA approval is 2027-2028. Rescheduling would then follow in 2028-2029. Mid-range estimate: 2030.

Important nuance: FDA approval and rescheduling means pharmaceutical psilocybin for approved indications in clinical settings. It does not mean recreational use, home use, or broad access outside medical prescription. Regulated medical access would look more like ketamine (Schedule III, medical prescription required, in-office administration) than anything resembling the Oregon service center model.